Navigation Links
Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
Date:6/8/2009

"Further, carfilzomib has been generally well tolerated, and the compound's selectivity appears to avoid the off-target effects, such as peripheral neuropathy, associated with currently available proteasome inhibitors."

Adverse events were generally mild and manageable and carfilzomib has been well tolerated for up to one year. Of 31 patients treated, 29 percent have received 12 full cycles of treatment.

These data were reported by Dr. Stewart in an oral presentation, titled "# 0474: Safety and Efficacy Update of PX-171-004, an Open-label Phase II Trial of Carfilzomib in Relapsed Multiple Myeloma," on Saturday, June 6, 2009.

Carfilzomib Combination with Lenalidomide is Well-Tolerated; Achieves Responses in Heavily Pre-treated Patients at Low Doses

Positive preliminary data from an ongoing Phase 1b dose-escalating trial of carfilzomib in combination with lenalidomide and low-dose dexamethasone in relapsed and refractory patients was presented by Michael Wang, M.D., of the University of Texas MD Anderson Cancer Center on Sunday, June 7, 2009. The Phase 1b clinical trial is designed to evaluate safety and to establish a maximum-tolerated dose of carfilzomib in combination with lenalidomide and dexamethasone administered on a 28-day treatment cycle. Lenalidomide in combination with dexamethasone is currently indicated for use in patients with multiple myeloma who have had at least one prior therapy.

To date, the combination of carfilzomib and lenalidomide was well tolerated in heavily pre-treated patients and adverse events were manageable. The most common adverse events reported include anemia and fatigue. No cases of peripheral neuropathy, a common adverse event associated with approved proteasome inhibitors, have been reported. A maximum-tolerated dose has not yet been established and dose-escalation in this trial continues.

Sixty-one percent of the
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Proteolix Raises $79 Million in Series C Financing
4. Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
5. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
6. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
7. Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting
8. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
9. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
10. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
11. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... Park Systems ... advanced scientific research into new classes of Nanoscale Graphene-based materials poised to revolutionize ... 'the wonder material of the 21st Century' by the researchers who were awarded ...
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome and ... insights on mechanics of fecal microbiota transplantation in C. difficile patients. , SAN ... of patients undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Matrix ... announced that it has hired Gem Swartz to head up its account management department ... account director. Both Gem and Amanda bring senior account management and delivery expertise to ...
(Date:6/30/2015)... Dr. Samadi Prostate Cancer Center in New York ... new genetic testing methods for men with an elevated PSA ... Dr. Samadi,s Prostate Cancer Center is ... and optimizing the diagnosis of prostate cancer, both pre-biopsy and ... these revolutionary genetic tests to men with an elevated PSA ...
Breaking Biology Technology:How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Matrix Marketing Group Expands Client Services Team 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5
... OAKS, Calif., June 24, 2011 Amgen (NASDAQ: ... Medicinal Products for Human Use (CHMP) of the European ... that Vectibix® (panitumumab) be approved for use in the ... and in second-line in combination with FOLFIRI in patients ...
... are exposed to light, they blink in a ... at the University of Pennsylvania have shown that ... new insight into this mysterious blinking behavior. ... Drndic,s group, including graduate student Siying Wang and ...
... BioNeutral Group Inc., (OTCBB: BONU.ob) today announced it ... of their revolutionary Cold Sterilant and Cleaning/Odor Products ... selected by New Jersey based T.U.C.S. Cleaning Services ... distribution company, because of the superior effectiveness of ...
Cached Biology Technology:Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 2Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 3Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 4Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 5Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 6Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 7Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 8Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 9Amgen Receives Positive CHMP Opinion for Vectibix® (Panitumumab) in Combination With Chemotherapy 10Penn physicists observe 'campfire effect' in blinking nanorod semiconductors 2Penn physicists observe 'campfire effect' in blinking nanorod semiconductors 3BioNeutral Starts Commercial Deployment of Its Ygiene 206 Sterilant and Ogiene Products Within Port Authority Facilities Using T.U.C.S. Cleaning Services 2BioNeutral Starts Commercial Deployment of Its Ygiene 206 Sterilant and Ogiene Products Within Port Authority Facilities Using T.U.C.S. Cleaning Services 3BioNeutral Starts Commercial Deployment of Its Ygiene 206 Sterilant and Ogiene Products Within Port Authority Facilities Using T.U.C.S. Cleaning Services 4
(Date:6/30/2015)... June 30, 2015 To bolster its efforts and ... Corp. announced today the addition of two new team members. ... board advisor and David Raviv will act as ... HYPR Corp.,s commitment to providing the most secure solutions for ... co-founded Layer 7 Technologies, a provider of security and ...
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
(Date:6/29/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... America Biomedical Sensors market is estimated at $0.65 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... from the Luxembourg Centre for Systems Biomedicine (LCSB) of ... in the brain can produce a substance that prevents ... assumed that only certain fungi produced itaconic acid. A ... Metabolomics Group at LCSB, and Dr. Alessandro Michelucci has ...
... reporting new outbreaks and the increased spread of Cassava Brown ... virus could cause a 50 percent drop in production of ... income for 300 million Africans. , The "pandemic" of ... been looking to the otherwise resilient cassava plantwhich is also ...
... scientists, writing in the journal Nature Geoscience , have ... an unexpected cooling effect on the world,s climate by making ... on to tiny particles suspended in the air. When the ... It has been known for some decades that the number ...
Cached Biology News:LCSB discovers endogenous antibiotic in the brain 2Scientists alarmed by rapid spread of Brown Streak Disease in cassava 2Scientists alarmed by rapid spread of Brown Streak Disease in cassava 3Scientists alarmed by rapid spread of Brown Streak Disease in cassava 4Organic vapors affect clouds leading to previously unidentified climate cooling 2
Applications: Western blotting ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
Biology Products: